MSC SPM Biosynthesis for Osteoarthritis Inflammation Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as NSAIDs and steroid injections, only manage symptoms and do not address the underlying disease progression, leading to eventual joint reconstruction or replacement surgeries, highlighting the need for non-surgical regenerative therapies that can regenerate joint tissues and reduce pain.
Innovation Solution
Stimulating mesenchymal stromal cells (MSCs) to produce specialized pro-resolving mediators (SPMs) by contacting them with fatty acid precursors or intermediates, such as DHA, to enhance inflammation resolution and tissue regeneration, using carriers like hydrogels for sustained delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If NSAIDs are used to manage pain in osteoarthritis, then pain relief is achieved, but the disease progression continues without treatment of underlying pathology
Solution Approach 1:
The patent uses specialized pro-resolving mediators (SPMs) as intermediary substances that mediate between the inflammatory state and tissue regeneration. SPMs are bioactive lipid molecules that actively resolve inflammation and promote tissue repair, serving as a bridge between pain management and disease modification. This intermediary approach allows simultaneous achievement of pain relief and disease progression control through a single therapeutic mechanism.
Solution Approach 2:
The patent employs mesenchymal stromal cells (MSCs) that possess intrinsic ability to produce SPMs and secrete trophic factors. These cells self-regulate the inflammatory response and promote tissue regeneration through their natural biological functions, reducing the need for external intervention and providing sustained therapeutic effect that addresses both symptoms and underlying pathology.
2Object-affected harmful factors
If steroid injections are administered to reduce inflammation, then inflammatory symptoms are suppressed, but cell death occurs and disease progression worsens
Solution Approach 1:
The patent converts the harmful inflammatory state into a beneficial resolution process by utilizing SPMs that actively transform inflammation into tissue repair. Instead of suppressing inflammation with steroids that cause cell death, the therapy uses biochemical mediators that guide the inflammatory response toward constructive outcomes, turning the harmful process into a regenerative one that eliminates inflammation while promoting cell survival and tissue regeneration.
Solution Approach 2:
The patent changes the biochemical parameters of the inflammatory environment by introducing SPMs that alter the molecular profile from pro-inflammatory to pro-resolving. This parameter change shifts the biological state from tissue destruction to tissue repair, achieving inflammation suppression without the cytotoxic effects of steroids through biochemical modulation rather than immunosuppression.
3Ease of operation
If conventional symptomatic management is used for osteoarthritis, then pain and symptoms are controlled, but joint tissues continue to degrade requiring surgery
Solution Approach 1:
The patent applies preliminary action by administering MSCs and SPMs before irreversible joint damage occurs. The therapy proactively promotes tissue regeneration and prevents further degradation rather than merely responding to established damage. This preliminary regenerative intervention maintains joint tissue integrity and delays or prevents the need for surgical intervention by addressing the underlying degenerative process early in the disease course.
Solution Approach 2:
The patent leverages the self-service capability of MSCs to continuously produce SPMs and secrete trophic factors that sustain tissue regeneration and protect against degradation. This self-sustaining biological system provides ongoing protection to joint tissues, maintaining structural integrity through continuous endogenous production of protective and regenerative molecules rather than requiring repeated external interventions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances inflammation resolution and promotes tissue regeneration, potentially reducing pain and disease progression in osteoarthritis, with MSCs producing SPMs like resolvins and maresins to treat inflammation and regenerate joint tissues.
Implementation Method 1
Methods of increasing mesenchymal stromal cell biosynthesis of specialized pro-resolving mediators
Data Source
AI summary
Methods of stimulating production of specialized pro-resolving mediators (SPMs) by mesenchymal stem cells (MSCs) are provided. The methods include contacting MSCs with one or more SPM fatty acid precursors, SPM intermediates, or a combination of two or more thereof. Also provided are compositions including the stimulated MSCs or conditioned media from the stimulated MSCs. Methods of treating or inhibiting inflammation are also provided, including administering to a subject stimulated MSCs or conditioned media from stimulated MSCs.